{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03778333",
      "OrgStudyIdInfo": {
        "OrgStudyId": "MSC-progressive MS"
      },
      "Organization": {
        "OrgFullName": "Karolinska Institutet",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Mesenchymal Stem Cells for Progressive Multiple Sclerosis_Sweden",
      "OfficialTitle": "Mesenchymal Stem Cells for Progressive Multiple Sclerosis_Sweden"
    },
    "StatusModule": {
      "StatusVerifiedDate": "December 2018",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "December 1, 2012",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "December 2016",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 31, 2016",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "January 14, 2015",
      "StudyFirstSubmitQCDate": "December 14, 2018",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "December 19, 2018",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "December 14, 2018",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "December 19, 2018",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Ellen Iacobaeus",
        "ResponsiblePartyInvestigatorTitle": "Principal investigator",
        "ResponsiblePartyInvestigatorAffiliation": "Karolinska Institutet"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Karolinska Institutet",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No",
      "IsUSExport": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "To assess the safety of a single dose of IV infusion of bone-marrow derived autologous Mesenchymal Stem Cells (MSCs) in Multiple Sclerosis (MS) with progressive disease status."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Autologous Mesenchymal Stem Cells",
          "Multiple Sclerosis"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Mesenchymal Stem Cells",
          "Multiple Sclerosis"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignInterventionModelDescription": "Open-label phase 1, single-center, pre-post comparison study",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "7",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Open label single arm study",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "All patients will be treated with 1 single dose of IV infusion of autologous bone-marrow derived mesenchymal stem cells (1-2 million cells/kg body weight) and their therapeutic response will be followed over 48 weeks.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Autologous mesenchymal stem cells"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Autologous mesenchymal stem cells",
            "InterventionDescription": "IV therapy with autologous bone-marrow derived mesenchymal stem cells",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Open label single arm study"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "To evaluate number of participants with an adverse event related to the treatment.",
            "PrimaryOutcomeDescription": "Adverse events is defined as any untoward or undesirable medical occurence in the form of signs, symptoms, abnormal findings or diseases that emerge during the study period, regardless of causal relationship to the study drug.",
            "PrimaryOutcomeTimeFrame": "48 weeks"
          },
          {
            "PrimaryOutcomeMeasure": "To evaluate effects on MS disease activity measured by cumulative number of MRI T2 lesions.",
            "PrimaryOutcomeDescription": "Brain MRI examination",
            "PrimaryOutcomeTimeFrame": "48 weeks"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "To evaluate effects on MS disease activity measured by change in EDSS (expanded disability status scale).",
            "SecondaryOutcomeDescription": "EDSS assessed by neurologist.",
            "SecondaryOutcomeTimeFrame": "48 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "To evaluate effect on peripheral blood immune cell populations.",
            "SecondaryOutcomeDescription": "Peripheral blood samples.",
            "SecondaryOutcomeTimeFrame": "24 weeks"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nDiagnosis of MS\n\nActive relapsing remitting MS (RRMS) as evidenced by presence of ≥ 1 clinically documented relapse in the past 12 months or ≥2 clinically documented relapses in the last 24 months.\nSecondary progressive MS with clinical progression as evidenced by an increase of 1 EDSS point (or 0,5 p if EDSS ≥ 5 at time for study start) in the last year or evidenced by ≥1 relapse or ≥ GEL at MRI performed within the last year.\nPrimary progressive MS with clinical progression as evidenced by an increase of 1 EDSS point (or 0,5 p if EDSS ≥ 5 at time for study start) in the last year.\nAge_ 18-65 years\nDisease duration: 2-20 years\nEDSS 3,0-7,0\n\nExclusion Criteria:\n\nSubtype of MS not fulfilling inclusion criteria\nTreatment with any immunosuppressive therapy, including natalizumab and fingolimod, within the 3 months prior to randomization\nTreatment with interferon-beta or glatiramer acetate within the 30 days prior to randomization\nTreatment with corticosteroids within the 30 days prior to randomization\nRelapse occurred during the 60 days prior to randomization\nPrevious history of a malignancy other than basal cell carcinoma of the skin or carcinoma in situ that has been in remission for more than one year\nSeverely limited life expectancy by another co-morbid illness\nActive or chronic severe infection.\nHistory of previous diagnosis of myelodysplasia or previous hematologic disease or current clinically relevant abnormalities of white blood cell counts\nPregnancy or risk or pregnancy (this includes patients that are unwilling to practice active contraception during the duration of the study)\neGFR < 60 mL/min/1.73m2 or known renal failure or inability to undergo MRI examination.\nInability to give written informed consent in accordance with research ethics board guidelines",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "65 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Karolinska Institute, Karolinska University Hospital Solna",
            "LocationCity": "Stockholm",
            "LocationZip": "171 76",
            "LocationCountry": "Sweden"
          },
          {
            "LocationFacility": "Karolinska Institute, Karolinska University Hospital",
            "LocationCity": "Stockholm",
            "LocationZip": "17176",
            "LocationCountry": "Sweden"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000009103",
            "ConditionMeshTerm": "Multiple Sclerosis"
          },
          {
            "ConditionMeshId": "D000020528",
            "ConditionMeshTerm": "Multiple Sclerosis, Chronic Progressive"
          },
          {
            "ConditionMeshId": "D000012598",
            "ConditionMeshTerm": "Sclerosis"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000020278",
            "ConditionAncestorTerm": "Demyelinating Autoimmune Diseases, CNS"
          },
          {
            "ConditionAncestorId": "D000020274",
            "ConditionAncestorTerm": "Autoimmune Diseases of the Nervous System"
          },
          {
            "ConditionAncestorId": "D000009422",
            "ConditionAncestorTerm": "Nervous System Diseases"
          },
          {
            "ConditionAncestorId": "D000003711",
            "ConditionAncestorTerm": "Demyelinating Diseases"
          },
          {
            "ConditionAncestorId": "D000001327",
            "ConditionAncestorTerm": "Autoimmune Diseases"
          },
          {
            "ConditionAncestorId": "D000007154",
            "ConditionAncestorTerm": "Immune System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M11212",
            "ConditionBrowseLeafName": "Multiple Sclerosis",
            "ConditionBrowseLeafAsFound": "Multiple Sclerosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M14567",
            "ConditionBrowseLeafName": "Sclerosis",
            "ConditionBrowseLeafAsFound": "Sclerosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M21466",
            "ConditionBrowseLeafName": "Multiple Sclerosis, Chronic Progressive",
            "ConditionBrowseLeafAsFound": "Progressive Multiple Sclerosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M3781",
            "ConditionBrowseLeafName": "Autoimmune Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M21251",
            "ConditionBrowseLeafName": "Demyelinating Autoimmune Diseases, CNS",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M21247",
            "ConditionBrowseLeafName": "Autoimmune Diseases of the Nervous System",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M6061",
            "ConditionBrowseLeafName": "Demyelinating Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9352",
            "ConditionBrowseLeafName": "Immune System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC10",
            "ConditionBrowseBranchName": "Nervous System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          }
        ]
      }
    }
  }
}